source
- BridgeBio Oncology shares tumble 24% as it narrows KRAS program focusBridgeBio Oncology Therapeutics saw its stock drop sharply after announcing a strategic shift. The company said it will scale back its broader pipeline to concentrate resources on its lead KRAS in…
- FDA places partial hold on Biohaven epilepsy drug BHV-7000 amid $350 million licensing dealThe U.S. Food and Drug Administration issued a partial clinical hold on enrollment for Biohaven’s epilepsy candidate BHV-7000 after rodent studies raised questions about drug metabolites. The hold…